ProKidney Earnings Call Transcripts
Fiscal Year 2026
-
Rilparencel, an autologous cell therapy for advanced CKD, is in phase III trials aiming to delay or prevent dialysis and improve patient outcomes. Key data readouts are expected in 2027 and 2029, with a large market opportunity and favorable safety profile supporting future commercialization.
-
The meeting approved all director nominees and auditor ratification, confirmed strategic progress on rilparencel's clinical development, and outlined plans for Phase III completion in 2026 with a key data readout expected in Q2 2027.
-
Rilparencel, an autologous cell therapy, is advancing through a pivotal phase III trial for advanced CKD, with top-line data expected in Q2 2027. Phase II results showed significant improvement in kidney function and strong safety, while manufacturing and commercial preparations are underway.
Fiscal Year 2025
-
The company is advancing an autologous cell therapy for advanced CKD, with phase III trials over 50% enrolled and an accelerated approval readout expected in Q2 2027. Strong phase II data, a robust safety profile, and significant market potential support commercial prospects.
-
The conference highlighted significant progress in the Phase III program for advanced CKD, including FDA alignment on accelerated approval using eGFR slope and a robust effect size. Financially, the company is well-funded through mid-2027, with a large addressable market and strong manufacturing capabilities.
-
Phase II data showed a significant reduction in kidney function decline with rilparencel, and detailed results will be presented at ASN Kidney Week. The phase III PROACT 1 trial is over 50% enrolled, targeting advanced CKD, with accelerated approval readout expected in Q2 2027.
-
A cell therapy for advanced CKD showed strong Phase II results, with a 78% improvement in eGFR decline and plans for accelerated approval based on a single Phase III trial. Manufacturing and commercial readiness are in place, with key data and regulatory updates expected in the next year.
-
Significant operational reset in 2024 led to resumed clinical programs and enhanced trial diversity. Phase 2 and interim phase 2b results show kidney function stabilization in high-risk patients, with a robust safety profile. Phase 3 pivotal trial is underway, with top-line results expected by end of 2027.
Fiscal Year 2024
-
Regulatory and clinical milestones are set for 2025, including key data from REGEN-007 and updates on the accelerated approval pathway. Focus remains on late-stage CKD patients, with manufacturing and financial resources in place to support progress through 2027.
-
Rilparencel, a cell therapy for advanced diabetic kidney disease, demonstrated kidney function stabilization in phase 2 trials and is now in a pivotal phase 3 study. FDA feedback allows a single trial for approval, with updates on accelerated pathways and new clinical data expected next year.
-
Rilparencel, an autologous cell therapy for advanced diabetic kidney disease, is advancing through a focused phase III program after regulatory and manufacturing improvements. FDA supports a single pivotal trial and accelerated approval using eGFR slope, with key data and regulatory milestones expected in 2025.
-
Rilparencel, an autologous cell therapy for advanced diabetic CKD, has shown promising efficacy and safety in phase II trials, leading to a focused phase III study with top-line results expected in 2027. Regulatory strategy leverages RMAT designation, and key data and updates are anticipated in 2025.
-
REACT, an autologous cell therapy for advanced diabetic kidney disease, showed promising phase II results with stabilization of kidney function and strong safety. The company is now focusing on a single U.S. phase III trial, leveraging regulatory flexibility and improved manufacturing to accelerate development.
-
Interim phase II REGEN-007 results show Rilparencel preserved kidney function in high-risk diabetic CKD patients, with an 18-month eGFR decline of -1.3 mL/min versus -6.2 mL/min in matched controls. Safety was consistent with prior studies, and phase III trials are underway.